Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...

CRF: Circulating recombinant form; NNRTI: Non-nucleoside reverse-transcriptase inhibitor; NRTI: Nucleos(t)ide analog reverse-transcriptase inhibitor. Eight nucleos(t)ide analog reverse ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

The following is a summary of “High-density lipoprotein anti-inflammatory capacity and acute kidney injury after cardiac and ...

Generally, the dual NRTI backbone treatment of combination with a non-NRTI (NNRTI) or protease inhibitor (PI) should comprise a cytidine analogue (lamivudine, emtricitabine) and a thymidine ...

More than 46,000 of them had been prescribed a form of HIV-suppressing medications known as reverse transcriptase (RT) inhibitors. Among this subgroup, Alzheimer's diagnoses occurred in about 2.5 ...

Cas9, a technology that has moved from lab to clinic at lightning speed. Scientists have already used gene editing to improve ...

Launched in April 2024 as part of Secretary of Education Miguel Cardona ’s Raise the Bar initiative, the Postsecondary Success Recognition Program highlights institutions that demonstrate exceptional ...

This important study presents the first identification of the odorant receptor for the trail pheromone in termites. The evidence supporting the conclusions is compelling, with state-of-the-art ...